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http://dx.doi.org/10.1016/j.kjms.201
1607-551X/Copyright ª 2014, KaohsiuAbstract Bladder urothelial carcinoma is rare in young adults and occurs more commonly
in older individuals. The aim of this study was to compare the clinical behavior, pathologic
characteristics, and prognosis of urothelial carcinoma of urinary bladder in young versus old-
er adults. A retrospective review of our records between 2007 and 2013 identified 56 pa-
tients (42 males and 14 females) with transitional cell carcinoma of the bladder who were
less than 40 years old. Clinical and pathological parameters of patients who were less than
40 years of age were compared with those of a series of patients older than 40 years of age
(the control group) during the same period. A survival analysis was performed using the Ka-
planeMeier method and log-rank test, and Cox regression was performed to identify clinical
parameters that affected the clinical outcomes. The mean age was 29.21 years (range, 5e40
years) for patients less than 40 years old and 61.66 years (range, 41e75) for those older than
40 years. The mean follow-up was 40.26 months (range, 12e65 months) for young patients
and 42.57 months (range, 12e72 months) for the older patients. Young bladder cancer pa-
tients had smaller-sized tumors (less than 3 cm), less high-grade cancers, higher papillary
urothelial neoplasms of low malignant potential, and low-grade tumors than patients older
than 40 years. Multivariate logistic regression analysis predicted tumor recurrence in young
patients with high-grade tumors [odds ratio (OR), 1.959; 95% confidence interval (CI), 1.235
e2.965; p Z 0.046] and tumors larger than 3 cm (OR, 1.772; 95% CI, 1.416e1.942;
pZ 0.032). The 5-year overall survival rate was 100% for young patients and 88.1% for older
patients. No difference was observed in the recurrence-free (p Z 0.321) and progression-
free (p Z 0.422) survival rates between the two groups. We concluded that although theeclare no conflicts of interest.
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Urothelial carcinoma in young adults 467clinical stage distribution, natural history, and outcomes of bladder urothelial cancer in
young adults are similar to those in their older counterparts, clinicians must be aware that
patients under 40 years of age presented with higher-grade and larger (>3 cm) tumors and
are more likely to experience tumor recurrence.
Copyright ª 2014, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Transitional cell carcinoma (TCC) of the bladder is un-
common below the age of 40 years (1%) [1,2]. There is no
univocity on clinical outcomes of such neoplasms. Ac-
cording to some authors, such tumors are noninvasive low-
grade tumors with low recurrence rate and, therefore, an
improved prognosis [3e6]. In contrast, some studies have
observed similar patterns in younger and older patients
[1,7e9]. In our study, we evaluated clinical behavior,
pathological outcomes, and disease recurrence and sur-
vival in patients with bladder TCC who were younger than
40 years of age. We compared our data with a matched
cohort of older patients (older than 40 years) with bladder
TCC.
Materials and methods
We retrospectively reviewed our medical records between
May 2007 and June 2013, and identified 56 patients (42
males and 14 females) with TCC of the bladder who were
less than 40 years old. Demographic data, including pa-
tients’ age, sex, presenting symptoms, initial transurethral
pathology, tumor diameter and locations, stages and
grades at initial transurethral resection, recurrence events
and disease progression to different stages or grades, and
disease status, were collected. We also reviewed and
selected a series of patients older than 40 years of age by a
case-matched analysis as the control (comparison) group,
with a case/control rate of 1:2, during the same period.
The 2004 World Health Organization (WHO) International
Society of Urologic Pathology and 2002 tumor-stage classi-
fication were used to evaluate the stages and grades of
bladder cancer [10e12]. Patients with nontransitional
bladder cancer, a history of known bladder cancer, and
upper tract urinary cancer were excluded from the study.
Disease recurrence was defined as the reappearance of the
disease at any site of the bladder and progression was
defined as conversion in tumor-stage classification of can-
cer. Additionally, recurrence- or progression-free periods
were defined between the dates of initial diagnosis of
bladder cancer and those of disease recurrence or
progression.
Statistical analysis
Patients younger than 40 years old were divided into two
subgroups according to age presentation: younger than 30
years old and between 30 and 40 years old. Data between
groups were analyzed using the Chi-square test.Recurrence-free, progression-free, and overall survival
analyses were performed using the KaplaneMeier method
and log-rank test. Multivariate Cox proportional hazards
analysis was performed to identify independent predictors
of the recurrence of TCC of the bladder in patients less
than 40 years old. These predictors included sex, tumor
stage, tumor grade, multifocality, and tumor size. All
statistical analyses were performed using SPSS ver.16.5
(Statistical Package for Social Sciences for Windows 16.5;
SPSS Inc., Chicago, IL, USA). A p value of <0.05 was
considered statistically significant.
Results
Between May 2007 and June 2013, 56 patients (42 males
and 14 females) with TCC of the bladder who were less than
40 years old were included in the young group and 112
patients with TCC of the bladder who were more than 40
years old were included in the control group. For the two
groups, the mean age at diagnosis was 29.21 years (range,
5e40 years) and 61.66 years (range, 41e75), with a male-
to-female ratio 3:1 and 3.3:1, respectively. The mean
follow-up time was 40.26 months (range, 12e65 months) for
young patients and 42.57 months (range, 12-72 months) for
older patients. A total of 25 patients (44.6%) were under
the age of 30 years, and 31 (55.3%) were between 31 and 40
years of age. Macroscopic hematuria was the presenting
symptom in 41 patients (73.2%) in the young group and in 79
patients (70.5%) in the older group. The clinical charac-
teristics of younger patients and their older counterparts
are presented in Table 1. Bladder urothelial cancer tumors
occurring in patients 40 years or younger were predomi-
nantly 3 cm in size and of low grade. As shown in Table 1,
the young group had significantly higher papillary urothelial
neoplasms of low malignant potential, low-grade tumors
(percentage of papillary urothelial neoplasms of low ma-
lignant potential, 28% vs. 16%; low-grade tumors, 64% vs.
49%; p Z 0.041), tumors of 3 cm diameter (89% vs. 61%;
p < 0.001), and a lower recurrence rate (30% vs. 47%,
p Z 0.040). Multivariate logistic regression analysis pre-
dicted tumor recurrence in young patients with high-grade
tumors [odds ratio (OR), 1.959; 95% confidence interval
(CI), 1.235e2.965; pZ 0.046] and tumors larger than 3 cm
(OR, 1.772; 95% CI, 1.416e1.942; p Z 0.032) (Table 2).
The KaplaneMeier method was used to estimate the
recurrence-free, progression-free, and overall survival
rates. The 5-year overall survival rate was 100% for young
patients and 88.1% for older patients. No difference was
observed in the recurrence-free (p Z 0.321) and
progression-free (p Z 0.422) survival rates between the
two groups (Fig. 1).
Table 1 Clinical characteristics of bladder urothelial cancer patients younger and older than 40 years.
Young group (40 y) Old group
(>40 y)
p
<30 y 31e40 y Total
Patients, n (%) 25 (44.6) 31 (55.4) 56 (100) 112
Mean age (range, y) 29.21 (5e40) 61.66 (41e75)
Mean follow up (range, mo) 40.26 (12e65) 42.57 (12e72) 0.136
Males/females, n 18/7 24/7 42/14 86/26 0.867
Clinical presentation, n (%)
Microscopic hematuria 3 7 10 (17.8) 22 (19.6) 0.175
Macroscopic hematuria 20 21 41 (73.2) 79 (70.5)
UTIs 2 3 5 (9) 11 (9.9)
Stage at presentation, n (%)
Ta 21 20 41 (73.3) 62 (55.4) 0.102
T1 4 7 11 (19.6) 22 (19.6)
T2 0 3 3 (5.4) 22 (19.6)
T3 0 1 1 (1.7) 6 (5.4)
Grade at presentation, n (%)
PUNLMP 7 9 16 (28.6) 19 (16.9) 0.041
Low 14 22 36 (64.3) 55 (49.2)
High 1 3 4 (7.1) 38 (33.9)
Multifocality (>1 lesions), n (%) 2 15 17 (30.3) 48 (42.8) 0.063
Tumor size, n (%)
3 cm 25 25 50 (89.3) 69 (61.6) <0.001
>3 cm 0 6 6 (10.7) 43 (38.4)
Tumor recurrence, n/N (%) 5/25 12/31 17/56 (30.3) 53/112 (47.3) 0.040
Tumor progression, n/N (%) 4/25 8/31 12/56 (21.4) 26/112 (23.2) 0.661
PUNLMP Z papillary urothelial neoplasms of low malignant potential; UTI Z urinary tract infection.
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Urothelial carcinoma of urinary bladder in patients younger
than 40 years of age is rare, with an incidence rate of onlyTable 2 Multivariate logistic regression analysis of pre-
dictors for tumor recurrence in patients younger than 40
years old.
Variable OR 95% Cl p
Sex
Male 1.000 0.132e12.038 0.842
Female 1.260
Tumor stage
Superficial
(Ta, T1)
1.000 0.890e1.981 0.056
Muscle invasive
(T2, T3)
1.752
Tumor grade
PUNLMP 1.000 1.235e2.965 0.046
Low 1.000
High 1.959
Multifocality
1 1.000 0.938e3.228 0.544
>1 2.324
Tumor size
3 cm 1.000 1.416e1.942 0.032
>3 cm 1.772
CIZ confidence interval; ORZ odds ratio; PUNLMPZ papillary
urothelial neoplasms of low malignant potential.0.8% [13]. There is a debate in the literature regarding the
clinical behavior and outcomes of bladder urothelial neo-
plasms in younger patients compared with older patients.
Our data confirmthe results of previous studies and showthat
patients aged 40 years or younger have similar clinical pre-
sentation and disease outcome to their older counterparts,
whereas some pathological parameters differ statistically.
In our study, younger patients had fewer high-grade
cancers than older patients (7% vs. 33%) and fewer tumors
>3 cm in size, which was similar to the findings of previous
studies [13e16]. According to a recent review by Paner
et al. [13], although there is a predominance of low-grade
tumors in the first three decades of life, the grade distri-
bution of bladder urothelial cancer in older patients is not
exactly comparable to those in the fourth decade of life.
In our study, a male predominance was observed (mal-
e:female ratio 3:1) in patients below 40 years of age, which
is similar to those reported in previous studies [7,17,18]. In
both the young and the older groups, the major presenting
symptom was macroscopic hematuria, and no significant
difference was observed between the younger and older
patients. In a review by Greenfield et al. [19] of 342 chil-
dren with gross hematuria, causes of which include infec-
tion, urolithiasis, and malignancy, only three were
diagnosed to have bladder urothelial carcinoma.
Furthermore, in the younger group, 17 patients (30%)
had a recurrence and 12 of them progressed to higher
stage, whereas in the older group, 53 (47%) had a recur-
rence and 26 progressed to higher disease; this finding is
supported by previous study results [9]. We have indicated
that stage distribution of patients aged 40 years or less with
Figure 1. Survival curves for the young (40 years) and older (>40 years) groups. (A) Overall survival probability in younger
versus older patients (p Z 0.599). (B) Recurrence-free survival probability in younger versus older patients (p Z 0.321). (C)
Progression-free survival probability in younger versus older patients (p Z 0.422).
Urothelial carcinoma in young adults 469bladder urothelial carcinoma was not significantly different
from their older counterparts, which is similar to the find-
ings of some published studies. In contrast, older patients
had higher invasive disease which some studies indicated
were due to mutations on chromosomes 8, 9, 11, and 17 and
often presented in older patients with a longer time to
carcinogenesis [7,20,21]. Unfortunately, our study did not
perform an extensive analysis because of the relatively
small number of patients, lack of information, and short
follow-up period, which are the major limitations of this
retrospective review. Future studies are needed to confirm
the exact clinical behavior and outcomes of bladder uro-
thelial cancer in younger adults compared with those in
their older counterparts.Conclusion
Our results suggest that most of the patients younger than
40 years with urothelial bladder cancer have tumors that
are 3 cm in size (89.3%) and of low grade (64.3%).
Although the clinical stage distribution, natural history, and
outcomes of bladder urothelial cancer in young adults are
similar to those in their older counterparts, clinician must
be aware that patients under 40 years of age presented
with higher-grade and larger (>3 cm) tumors are more
likely to experience tumor recurrence.References
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